Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00574717
Other study ID # 2004H0157
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received December 11, 2007
Last updated October 18, 2012
Start date December 2007
Est. completion date September 2010

Study information

Verified date October 2012
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

To determine if wearing a moderate spectacle under-correction (3.00D) and performing activities designed to stimulate accurate accommodation during a 15-month period will enhance emmetropization in highly hyperopic (between +5.00D and +7.00D) 3-month old infants.


Description:

The purpose of the project is to determine if emmetropization can be enhanced in very farsighted babies. We will give them glasses with a partial correction, an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. This 'boost' is meant to enable very farsighted babies to use their eyes in a normal way and emmetropize as normal infants. This partial correction would be given at 3 months of age for a period of up to 15 months. A program of visual engagement is also provided in order to encourage the normal development and use of accommodation. As changes in farsightedness occur, the power of the glasses will be reduced at follow up appointments to keep the farsightedness within the zone of effective emmetropization. Once an infant reaches a normal amount of farsightedness, the glasses would be discontinued.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 8 Weeks to 20 Weeks
Eligibility Inclusion Criteria:

- 3 months of age (between 8 weeks and 20 weeks)at the baseline examination

- Either gender, any ethnicity

- Birthweight greater than 2500g

- Normal pregnancy and delivery (including Cesarean section delivery but excluding serious complications or conditions such as eclampsia or rubella)

- Hyperopia of +5.00D or more but less than +7.00D spherical equivalent refractive error in each eye by cycloplegic retinoscopy using cyclopentolate 1%

- Currently under the care of a pediatrician

Exclusion Criteria:

- Anisometropia greater than 1.00D (difference in spherical equivalent)

- Strabismus

- Previous history of difficulty with pupillary dilation

- History of cardiac, liver, asthma, or other respiratory disease

- History of ocular disease or active ocular inflammation

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Spectacles
Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.

Locations

Country Name City State
United States The Ohio State University College of Optometry Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Ohio State University The Ohio Lions Eye Research Foundation

Country where clinical trial is conducted

United States, 

References & Publications (8)

Anker S, Atkinson J, Braddick O, Nardini M, Ehrlich D. Non-cycloplegic refractive screening can identify infants whose visual outcome at 4 years is improved by spectacle correction. Strabismus. 2004 Dec;12(4):227-45. — View Citation

Atkinson J, Anker S, Bobier W, Braddick O, Durden K, Nardini M, Watson P. Normal emmetropization in infants with spectacle correction for hyperopia. Invest Ophthalmol Vis Sci. 2000 Nov;41(12):3726-31. — View Citation

Hung LF, Crawford ML, Smith EL. Spectacle lenses alter eye growth and the refractive status of young monkeys. Nat Med. 1995 Aug;1(8):761-5. — View Citation

Ingram RM, Gill LE, Lambert TW. Effect of spectacles on changes of spherical hypermetropia in infants who did, and did not, have strabismus. Br J Ophthalmol. 2000 Mar;84(3):324-6. — View Citation

Mutti DO, Mitchell GL, Jones LA, Friedman NE, Frane SL, Lin WK, Moeschberger ML, Zadnik K. Axial growth and changes in lenticular and corneal power during emmetropization in infants. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3074-80. — View Citation

Mutti DO, Mitchell GL, Jones LA, Friedman NE, Frane SL, Lin WK, Moeschberger ML, Zadnik K. Refractive astigmatism and the toricity of ocular components in human infants. Optom Vis Sci. 2004 Oct;81(10):753-61. — View Citation

Schaeffel F, Glasser A, Howland HC. Accommodation, refractive error and eye growth in chickens. Vision Res. 1988;28(5):639-57. — View Citation

Smith EL 3rd, Hung LF. The role of optical defocus in regulating refractive development in infant monkeys. Vision Res. 1999 Apr;39(8):1415-35. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome will be to determine if the criterion level for emmetropization (=+3.00D by 18 months of age) is met and maintained by at least 70% of treated infants. 15 months No
See also
  Status Clinical Trial Phase
Completed NCT06046209 - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens N/A
Completed NCT05656885 - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses N/A
Completed NCT02423109 - Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses N/A
Completed NCT01392950 - Clinical Study of Clariti Monthly Contact Lens N/A
Withdrawn NCT00765960 - Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure
Completed NCT00520689 - Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens Phase 3
Completed NCT05538182 - Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children N/A
Enrolling by invitation NCT05976750 - Air Optix® Night and Day® Aqua Daily Wear
Completed NCT02575911 - Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study N/A
Completed NCT05735990 - Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia
Withdrawn NCT03671096 - Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction N/A
Recruiting NCT02279446 - Development of a Validated Chart for Intermediate Vision Assessment N/A
Completed NCT01951573 - Evaluation of a New Daily Disposable Multifocal Contact Lens Design N/A
Completed NCT02060539 - Multicenter Dispensing Study of Biofinity Lenses in Extended Range N/A
Completed NCT01467557 - Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY
Completed NCT01228591 - Pilot Dispensing Evaluation of a Plus Power Lens N/A
Completed NCT03722784 - Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear N/A
Completed NCT03688672 - Apioc Contact Lens Feasibility N/A
Completed NCT05741450 - A Clinical Comparison of Two Soft Contact Lenses N/A
Completed NCT01912781 - Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers N/A